VRCI Stock Overview
Develops prognostic and diagnostic tests for kidney transplant patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Verici Dx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.034 |
| 52 Week High | UK£0.13 |
| 52 Week Low | UK£0.028 |
| Beta | 1.82 |
| 11 Month Change | -20.59% |
| 3 Month Change | -50.00% |
| 1 Year Change | -66.25% |
| 33 Year Change | -95.34% |
| 5 Year Change | n/a |
| Change since IPO | -90.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| VRCI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -6.0% | -0.3% |
| 1Y | -66.3% | -22.4% | 6.1% |
Return vs Industry: VRCI underperformed the UK Biotechs industry which returned -21.1% over the past year.
Return vs Market: VRCI underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| VRCI volatility | |
|---|---|
| VRCI Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VRCI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: VRCI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Sara Barrington | www.vericidx.com |
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
Verici Dx plc Fundamentals Summary
| VRCI fundamental statistics | |
|---|---|
| Market cap | UK£8.19m |
| Earnings (TTM) | -UK£3.81m |
| Revenue (TTM) | UK£3.44m |
2.4x
P/S Ratio-2.1x
P/E RatioIs VRCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCI income statement (TTM) | |
|---|---|
| Revenue | US$4.33m |
| Cost of Revenue | -US$3.00k |
| Gross Profit | US$4.34m |
| Other Expenses | US$9.15m |
| Earnings | -US$4.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.07% |
| Net Profit Margin | -110.99% |
| Debt/Equity Ratio | 0% |
How did VRCI perform over the long term?
See historical performance and comparison